A recent study has assessed the safety and efficacy of a selective inhibitor of JAK1 SHR0302426 in rheumatoid arthritis patients, and this molecule has now entered a Phase 3 clinical trial (NCT04333771). Here, JAK1 is linked to rheumatoid arthritis.